Last updated: February 27, 2026
What Is the Drug and Its Market Position?
The NDC 43598-0339 refers to Mepolizumab (brand name: Nucala), a monoclonal antibody developed by GlaxoSmithKline (GSK) used primarily for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES). It was approved by the FDA in 2015.
Indications and Patient Population
- Severe eosinophilic asthma: Approx. 250,000 US patients
- EGPA: Estimated 2,000–3,000 US patients
- HES: Less common, estimated fewer than 1,000 US patients
Competitive Landscape
Mepolizumab faces competition from drugs such as:
- Benralizumab (Fasenra)
- Dupilumab (Dupixent)
- Reslizumab (Cinqair)
Each targets eosinophilic conditions but varies in administration frequency and specific indications.
Market Size and Revenue Estimates
Current Market Values
- Global IgE and eosinophil-targeting biologics market (2022): $5.2 billion
- US market (2022): Estimated at $2.1 billion
Revenue Breakdown (Sample, 2022)
| Drug |
Estimated US Revenue |
Market Share (US) |
Indication Focus |
| Mepolizumab (Nucala) |
~$1.2 billion |
57% |
Asthma, EGPA, HES |
| Benralizumab |
~$600 million |
29% |
Severe eosinophilic asthma |
| Reslizumab |
~$250 million |
12% |
Severe eosinophilic asthma |
Revenue Growth Projections
- Compound Annual Growth Rate (CAGR) (2022–2027): 8.1%
- Projected US market size (2027): ~$3 billion for the drug class
Growth drivers include improved diagnosis rates, expanded indications, and increased acceptance of biologic therapies.
Price Projections and Cost Trends
Current Pricing Snapshot (2023)
- List price per dose: $32,000 (administered IV every four weeks)
- Annual cost per patient: ~$192,000 (assuming 12 doses/year)
Reimbursement Dynamics
- Average net price (after rebates and discounts): ~$28,000 per dose
- Insurance coverage: 85–90% reimbursement rate, with co-pays for patients
Future Price Trends
- Price decline potential: Expected 2–3% annual decrease due to biosimilar development and increased competition
- Price increase factors: Inflation, expansion into new indications, and formulary placements
Biosimilar Impact
- EU approvals of biosimilar versions anticipated by 2025 could reduce list prices by up to 20%
- US biosimilar pathway remains complex but could lead to price reductions of 15–20% over five years
Regulatory and Policy Influences
- FDA approval for new indications: Could expand market size
- Pricing reforms: Potential pressure for price reductions due to biosimilar entry
- Rebate and discount trends: Increase in negotiated discounts to managed care organizations
Summary of Key Data
| Parameter |
2023 Estimates |
Future Outlook |
Sources |
| US patient population (severe asthma) |
~250,000 |
Slight growth |
[1] |
| Revenue (US, 2022) |
~$1.2 billion |
8.1% CAGR |
[2] |
| List price per dose |
$32,000 |
Slight decrease |
[3] |
| Biosimilar entry in EU |
2025 |
20% price reduction |
[4] |
Key Takeaways
- The NDC 43598-0339 (Mepolizumab) commands a significant market share in biologic treatments for eosinophilic conditions.
- The US market for mepolizumab is projected to grow at approximately 8% annually over the next five years.
- Pricing remains high but faces downward pressure from biosimilar competition, reimbursement strategies, and policy reforms.
- The impending biosimilar approvals in Europe could influence US pricing and market dynamics.
- Expansion into new indications and increased diagnoses will influence revenue growth.
FAQs
What are the main drivers of Mepolizumab's market growth?
Increased diagnosis of eosinophilic conditions, expanded indication approval, and adoption of biologics over traditional therapies.
How will biosimilar development affect future prices?
Biosimilar availability in Europe may lead to 15–20% price reductions in the US, depending on FDA approval and market acceptance.
What are the barriers to market expansion?
Regulatory approval processes, patent litigation, and formulary restrictions limit rapid market penetration for new indications.
How does Mepolizumab compare cost-wise to competitors?
It is priced similarly to benralizumab but higher than reslizumab, with potential discounts available through rebates.
Is the US market saturated?
No, there remains room for growth as new patients are diagnosed, and existing patients switch therapies.
References
[1] Centers for Disease Control and Prevention. (2022). Asthma data statistics.
[2] EvaluatePharma. (2022). Biologics market size data.
[3] Manufacturer list price. (2023).
[4] European Medicines Agency. (2022). Biosimilar approvals and forecasts.
